

24-26th March, 2026 | London, UK

www.bacteriophage-summit.com

SAVE UP TO £1000
BY REGISTERING
BEFORE FRIDAY, 12TH
DECEMBER

8th Annual

Bacteriophage Therapy Summit

Delivering Regulatory-Ready, Precision Phages to Combat AMR & Beyond

**Translate Your Bacteriophage Therapies
into Market-Ready Products by Navigating
Regulatory Frameworks, Scaling GMP
Manufacturing & Delivering Clinically
Proven, Precision-Engineered Solutions
Across Human & Non-Human Health**


Expert Speakers Include:



Deborah Birx
Chief Executive
Officer
**Armata
Therapeutics**



**Alexander
Sulakvelidze**
Chief Executive
Officer
Intralytix



Gregorio Iraola
Chief Executive
Officer
KinzBio



Jason Clark
Chief Scientific
Officer
NexaBiome



Jean-Paul Pirnay
Head of the
Laboratory for
Molecular and
Cellular Technology
**Queen Astrid
Military Hospital**



Sofia Corte-Real
Chief Scientific
Officer
Technophage

+44 (0)20 3141 8700 @ info@hansonwade.com

www.bacteriophage-summit.com



WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Welcome to the Only Industry Dedicated Bacteriophage Conference

8th Annual
**Bacteriophage
Therapy Summit**
24-26th March, 2026 | London, UK

As antimicrobial resistance continues to escalate globally, bacteriophage therapies remain the leading alternative to traditional antibiotics. With multiple candidates advancing through clinical trials and regulatory agencies now articulating approval pathways, the field is poised to transition from early promise to real-world impact.

Moving to London in 2026, the **Bacteriophage Therapy Summit** is aligning itself with increasing regulatory definition in the UK & Europe and recent investment such as the EU Commission Grant. Returning for its 8th year, it remains the only industry-led, commercially focused meeting delivering regulatory clarity, clinically validated data, and practical routes to market for safe and scalable bacteriophage products.

Spanning **human** and **non-human health** applications, this year's summit gives phage drug developers the tools, insights and connections needed to:

-  **Navigate regulatory complexity** with confidence by understanding UK, EU and US pathways, streamlining the route for phage cocktails to reach approval
-  **Accelerate clinical progress** by leveraging shared trial learnings from real-world case studies spanning Phase I and II programmes across infectious diseases, oncology, immunology and chronic conditions
-  **Overcome manufacturing and scalability hurdles** in phage production, with practical approaches into in-house capacity building, outsourcing and bridging the GMP gap, enabling scalable phage production for commercial and clinical success
-  **Facilitate One Health opportunities** through cross-learnings between human health and veterinary medicine, agricultural pathogen control and aquaculture to fast-track phage development ubiquitously
-  **Strengthen national and regional ecosystems** by exploring how funding, infrastructure and translational hubs can accelerate commercial readiness
-  **Leverage cutting-edge tools** such as AI and Synthetic Biology to develop both natural and engineered phage cocktails and personalised treatments to enable unprecedented safety and efficacy for phages-derived products

Whether you're looking to accelerate clinical timelines, secure regulatory buy-in, streamline manufacturing, or build strategic alliances, join **55+ senior leaders in bacteriophage research** to move the field from promise to product.

Key Benefits of Attending



Navigate fragmented and evolving regulatory guidance with practical, phage-specific insights to streamline submissions, accelerate approvals, and prevent delays in getting therapies to patient **NexaBiome** and **PhagePro**



Overcome the complexities of late-phase clinical trial design to generate robust safety and efficacy evidence against current standards of care, driving regulatory confidence and commercial success of phage-based therapeutics, with new data from **Armata Therapeutics** and **Technophage**



Unlock the potential of emerging phage markets across animal health, agriculture and consumer products to harness novel applications and capture untapped commercial opportunities, featuring perspectives from **Intralix** and **Phagelux AgriHealth**



Explore novel phage modalities and engineering technologies to harness next-generation precision design, expanding therapeutic possibilities and advancing phage efficacy, highlighting **SNIPR Biome** and **Oxford Silk Phage Technologies**



Build scalable, high-throughput manufacturing systems that convert lab-scale innovation into reproducible, GMP-ready production while maintaining product integrity, consistency and cost efficiency, featuring insights from **Loughborough University** and **KinzBio**

The 8th Phage Summit in Numbers:



20+
Speakers



18+
Case Studies



11+
New
Organizations



10+
Networking
Hours



3+
Panel
Discussions

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

What's New For 2026?

8th Annual
**Bacteriophage
Therapy Summit**
24-26th March, 2026 | London, UK

Key Sessions you Can't Miss



Designing Scalable, Cost-Effective Manufacturing Platforms to Advance Phage Therapeutics Toward the Clinic

Danish Malik, Professor - Industrial Biotechnology, Loughborough University

1



Advancing Engineered Phages Toward Clinical Reality

Jonas Hink, Chief Medical Officer, SNIPR Biome

2



Proving the Potential: What Happens When Phage Therapy Reaches the Bedside

Jean-Paul Pirnay, Head of the Laboratory for Molecular & Cellular Technology, Queen Astrid Military Hospital

3



Strengthening Europe's Innovation & Preparedness Frameworks to Tackle Emerging Antimicrobial Threats

Raquel Rodríguez Alonso, PhD Policy Officer, European Commission

4



Reimagining Infection Prevention with Phage-Enhanced Medical Devices to Reduce Cardio Vascular-Associated Infections & Beyond

Stephanie Lesage, Chief Executive Officer, Oxford Silk Phage Technologies

5

Expanding Horizons: Novel Sectors, Modalities & Applications

Harnessing Phage as a Diagnostic Tool

Unlocking Phage Potential in Agriculture

Exploring Phage for Preventative Use

Reviving the Power of Lysins

Integrating Phage & Gene Editing

Phage-Inspired Biomaterials & Nanotechnology

New Companies for 2026 Include:



3

+44 (0)20 3141 8700 @ info@hansonwade.com

www.bacteriophage-summit.com



WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Your Expert Speakers

8th Annual
**Bacteriophage
Therapy Summit**
24-26th March, 2026 | London, UK

Human Health Biotech Leaders



Deborah Birx
Chief Executive Officer
Armata Therapeutics



Jason Clark
Chief Scientific Officer
NexaBiome



Stephanie Lesage
Co-founder and Chief
Executive Officer
**Oxford Silk Phage
Technologies**



Mimi Yen
Chief Executive Officer
PhagePro Incorporated



Jonas Hink
Chief Medical Officer
SNIPR Biome



Sofia Corte-Real
Chief Scientific Officer
Technophage



Subhendu Basu
Chief Executive Officer
Telum Therapeutics



Matthew Cummings
Chief Executive Officer
**Precisio Biotix
Therapeutics**



Amanda Burkardt
Chief Executive Officer
PhioGen

Animal Health & Consumer Pioneers



Alexander Sulakvelidze
Chief Executive Officer
Intralytix



Gregorio Iraola
Chief Executive Officer
KinzBio



Ben Swift
Lead Scientist
Carus Animal Health



William Marsh
Chief Executive Officer
PhageFarm



Matthew Tebeau
Chief Operating Officer
Phagelux AgriHealth

Leading Academic, Clinical & Governmental Experts



**Raquel Rodríguez
Alonso, PhD**
Policy Officer
European Commission



Francesca Hodges
Innovation Lead – Future
Medicines, Medicines
Discovery & Medicines
Manufacturing
Innovate UK



Antonia Scobie
Consultant & Research
Lead, Bone Infection Unit
**National Health Service
(NHS)**



Danish Malik
Professor of Industrial
Biotechnology
Loughborough University



Mark Sutton
Professor of Anti-Microbial
Therapy & Scientific Leader
- AMR and Healthcare
Biotechnology
**Kings College London &
UKHSA**



Jean Paul Pirnay
Head of the Laboratory
for Molecular & Cellular
Technology
**Queen Astrid Military
Hospital**



Catherine E.D. Rees
Professor of Microbiology
& Division Head
University of Nottingham



Ryszard Międzybrodzki
Head of the Medical
Center Ludwik
**Hirsfeld Polish
Academy of Sciences**



Colin Brown
Head of Antimicrobial
Resistance & Healthcare
Associated Infections &
Deputy Director: Epidemic &
Emerging Infections
UKHSA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Pre-Conference Workshop Day

Tuesday, March 24, 2026

Registration & Morning Coffee

9.00

Workshop A

9.30 - 12.30

Fixing Phage's Biggest Bottleneck: Building Sustainable Investment, Business Models & Reimbursement Pathways

The World Health Organization (WHO) warns that antimicrobial resistance (AMR) could cause 39 million deaths over the next 25 years, with annual deaths potentially exceeding 10 million by 2050 and costing the global economy up to \$1 trillion annually.

Despite growing urgency, phage therapy, one of the most promising solutions to AMR, continues to face a persistent investment drought, compounded by the lack of viable reimbursement and commercial models to sustain long-term innovation.

Join this interactive workshop to explore how developers and investors are breaking through these barriers to unlock scalable, sustainable phage therapy development by addressing:

- Why investment, business model uncertainty and lack of reimbursement pathways collectively remain the biggest bottlenecks slowing phage progress
- Lessons from biotech leaders proving commercial viability through creative partnerships, diversified pipelines and value-based frameworks
- How push and pull incentives can catalyze early investment, and what structural changes are needed to make them sustainable
- What evidence, milestones and health-economic data are needed to convince regulators and payers to act faster than bacteria can evolve

Workshop Leaders



Gregorio Iraola
Chief Executive
Officer
KinzBio

Lunch Break & Networking

12.30

Workshop B

1.30 - 4.30

Advancing Phage Therapeutics into Late-Stage Clinical Trials: Bridging Translational Gaps to Enable Regulatory & Commercial Success

As early clinical results generate growing enthusiasm, the phage field now faces the critical hurdle of translating promising preclinical and early-phase data into robust, late-stage clinical trials. Designing studies that satisfy regulatory expectations, demonstrate reproducible efficacy, and attract sustainable investment remains a defining challenge for the community.

Join this workshop to examine how leading developers are overcoming the translational, operational, and strategic barriers limiting late-stage progress:

- How can trial design, patient selection, and endpoints be optimized to demonstrate consistent efficacy across diverse infections and populations?
- What regulatory and manufacturing considerations must be addressed to align with IND/CTA and pivotal trial requirements?
- How can partnerships, data generation, and funding models evolve to de-risk and accelerate late-stage development?

Workshop Leaders



Deborah Birx
Chief Executive
Officer
**Armata
Therapeutics**



Sofia Corte-Real
Chief Scientific
Officer
Technophage

End Pre-Conference Workshop Day

4.30

Conference Day One

Wednesday, 25th March, 2026



8.00 Morning Registration & Breakfast

8.50 Chair's Opening Remarks

Building Scalable & Compliant Phage Manufacturing Processes that Bridge Discovery & the Clinic

9.00 Designing Scalable, Cost-Effective Manufacturing Platforms to Advance Phage Therapeutics Toward the Clinic



Danish Malik
Professor of Industrial
Biotechnology
Loughborough
University

- Exploring how developers are advancing small-scale, high-throughput optimisation systems to streamline phage production and de-risk clinical manufacturing
- Understanding the critical parameters that define yield and quality - from oxygen and pH control to seeding and harvest timing - and how these influence capsid integrity, potency, and downstream formulation
- Examining how partnerships between academic platforms, SMEs, and contract manufacturers can enable early-stage innovators to generate robust data packages without the prohibitive costs of full GMP infrastructure

9.30 Panel Discussion: Overcoming Scale-Up Bottlenecks While Protecting Product Consistency to Optimise Commercial Viability, Scalability, & Regulatory Acceptance

- Strategies for translating lab-scale processes into GMP production without compromising quality or yield
- Practical insights into host strain selection, propagation and purification workflows that scale
- How to manage cost of goods and production timelines while maintaining reproducibility across batches



Danish Malik
Professor of Industrial Biotechnology
Loughborough University



Gregorio Iraola
Chief Executive Officer
KinzBio



Sofia Corte-Real
Chief Scientific Officer
Technophage



10.30 Speed Networking Break

As the global phage community comes together once again for this year's summit, this dedicated session offers a unique opportunity to reconnect with familiar faces and meet many new ones too. Join peers spanning biotech, academia, healthcare and policy to strengthen collaborations, spark new ideas and build relationships that will continue driving the field forward long after the summit.

Redefining Phage Clinical Trial Design to Deliver Reliable Evidence & Secure a Sustainable Future for Phage Therapy

11.30 From Discovery to Clinic and Everything in Between: Intralytix's Path to Phage Therapies and Microbiome Modulation



**Alexander
Sulakvelidze**
Chief Executive Officer
Intralytix

New Featured
Company

- Outlining how Intralytix evolved from its origins in human therapeutic phage development to becoming a global pioneer in food safety and environmental biocontrol, leveraging these commercial successes to re-enter the human health space with multiple clinical-stage phage therapy programs
- Examining the ongoing technical and regulatory challenges facing the field, including the identification of potent therapeutic phages, ensuring scalability, and meeting cGMP standards under 21 CFR 111/117 and 210/211 to bridge discovery and clinical translation
- Showcasing Intralytix's proprietary PhageSelector™ and PhageEngine™ platforms, which integrate high-throughput screening, data science, and AI to refine phage-host pairing, guide cocktail formulation, and streamline scale-up for therapeutic and microbiome-modulating applications

Conference Day One

Wednesday, 25th March, 2026



Mimi Yen
Chief Executive Officer
**PhagePro
Incorporated**

12.00 Defining the Pathway for Phage Therapeutics in Global Health: Translating Outbreak Prevention from Concept to Clinic

- Building a clinical development framework for orally administered phage therapeutics targeting cholera prevention in low and middle income countries
- Designing human challenge models to establish clinical proof of concept and regulatory confidence for outbreak ready phage formulations
- Bridging regulatory, manufacturing and market access considerations to enable scalable and sustainable deployment of phage therapies as public health tools



12.30 Lunch & Networking Break

Expanding Bacteriophage Innovation into Emerging Sectors to Drive Wider Adoption & Value



William Marsh
Chief Executive Officer
PhageFarm

New Featured
Company

1.30 Translating Phage Science into Consumer Products to Drive Scalable, Regulated & Profitable Innovation

- Exploring the rise of phage-derived enzymes and actives in consumer health, hygiene and household applications
- Overcoming regulatory grey zones that limit commercialisation across cosmetics, OTC and household sectors
- Scaling production, ensuring stability and building viable business models for mainstream consumer adoption



Ben Swift
Lead Scientist
Carus Animal Health

New Featured
Company

2.00 Harnessing Phages to Modulate Rumen Microbiomes for Methane Reduction

- Investigate the potential of methanogen-specific phages to selectively modulate archaeal populations in the rumen, reducing methane emissions and improving feed efficiency in livestock
- Assess how phage-driven shifts in the rumen microbial community affect overall microbiome stability, nutrient cycling, and greenhouse gas production
- Explore parallels between methanogen-phage interactions in animals and the human gut, exploring the potential for phage therapies for dysbiosis-associated conditions such as inflammation and metabolic disorders



Matthew Tebeau
Chief Operating Officer
Phagelux AgriHealth

New Featured
Company

2.30 Unlocking Sustainable Agricultural Growth Through Phage Innovation to Deliver Proven ROI & Long-Term Adoption

- Demonstrating field-proven success in reducing bacterial burden and boosting yield across crops and livestock
- Overcoming farmer hesitancy through clear ROI, reliable trial design, and repeatable real-world validation
- Establishing scalable business models and strategic partnerships that drive durable adoption from farm to food chain



3.00 Afternoon Networking & Poster Session

Join the phage community for an interactive session exploring pioneering research, breakthrough phage technologies, and real-world solutions to accelerate access and adoption. Share your work, exchange ideas, connect with peers, and help shape the future of bacteriophage therapy. See full T&Cs online for eligibility.

Conference Day One

Wednesday, 25th March, 2026

Harnessing AI & Next-Generation Bacteriophage Modalities to Expand Therapeutic Possibilities Against AMR



Subhendu Basu
Chief Executive Officer
Telum Therapeutics

New Featured
Company

3.30 Reviving Confidence in Lysins Through Next-Generation Engineering to Deliver Real Therapies Against Resistant Infections

- Demonstrating how next-generation lysins achieve rapid, contact-driven bacterial killing with minimal resistance potential, while leveraging advanced protein engineering to reduce immunogenicity and enhance in vivo stability
- Translating lessons from earlier clinical attempts into a more predictive development pathway, emphasizing physiologically relevant in vivo models over serum-based assays to design smarter, risk-reduced clinical trials
- Highlighting how computational design, rational candidate selection and pragmatic early-access pathways are converging to unlock a truly viable route to clinical deployment of lysin therapeutics



Jonas Hink
Chief Medical Officer
SNIPR Biome

4.00 Advancing Engineered Phages Toward Clinical Reality

- Presenting results of FHD clinical study and clinical development plan for SNIPR001, a cocktail of engineered, CRISPR-armed phages targeting E. coli
- Discussing other uses of SNIPR001 based on *in vivo* preclinical data and a case study
- Outlining the critical steps toward building a regulatory and clinical evidence base that can support the first approvals of engineered phage products



Matt Cummings
Chief Executive Officer
Precisio Biotix

New Featured
Company

4.30 Translating Novel Modalities from Concept to Clinic to Strengthen Phage's Therapeutic Future

- Addressing CMC, stability, and delivery challenges unique to synthetic or protein-based antimicrobials
- Aligning development pathways with evolving regulatory expectations for non-traditional therapeutics
- Ensuring robust preclinical models and manufacturing scalability to accelerate real-world clinical adoption

5.00 Chair's Closing Remarks

5.05 End of Conference Day 1

“Attending the Bacteriophage Therapy Summit is an exciting opportunity for anyone passionate about microbiology, infectious diseases, or biotechnology. Conferences such as these could transform how we understand and harness bacteriophages. Beyond the science, it's a chance to engage with a vibrant, global community united by curiosity, creativity, and the potential of phage and phage-based approaches to revolutionize medicine and microbiology.”

Chief Executive Officer, Telum Therapeutics - 2026 Speaker

Conference Day Two

Thursday, 26th March, 2026

8th Annual
**Bacteriophage
Therapy Summit**
24-26th March, 2026 | London, UK

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



8.15 Morning Networking & Breakfast

8.50 Chair's Opening Remarks

Overcoming Undefined & Fragmented Regulatory & Reimbursement Barriers to Ensure Clinical Phase Approvals

9.00 Establishing a Clear & Predictable UK Regulatory Pathway to Accelerate Clinical Phase Access



Jason Clark
Chief Scientific Officer
NexaBiome

- Examining how MHRA, NICE and NHS England are shaping a national framework for phage therapy evaluation
- Understanding opportunities created by the Innovative Medicines Fund and adaptive licensing pilots
- Outlining the next steps needed to transition from compassionate-use approvals to standardised national access

9.30 Panel Discussion: Building a Unified Global Framework to Enable Scalable Phage Development, Investment Confidence & Market Access

- Comparing evolving regulatory approaches across regions to identify opportunities for alignment that de-risk development for investors
- Evaluating how harmonised guidance could accelerate approval timelines, reduce duplicated effort and strengthen the commercial case for phage therapies
- Exploring how global partnerships, data-sharing initiatives and transparent evidence standards can unlock greater investment, set new regulatory precedents and enable scalable, sustainable phage innovation



Catherine E.D. Rees
Professor of Microbiology &
Division Head
University of Nottingham



Jason Clark
Chief Scientific Officer
NexaBiome



Francesca Hodges
Innovation Lead – Future Medicines
Medicines Discovery & Medicines Manufacturing
Innovate UK



10.30 Morning Networking Break

11.30 Strengthening Europe's Innovation & Preparedness Frameworks to Tackle Emerging Antimicrobial Threats



**Raquel Rodríguez
Alonso**
Policy Officer
European Commission

New Featured
Organisation

- Exploring how Europe can build sustainable innovation pipelines to accelerate the development and deployment of next-generation antibacterial modalities, including phage-based and precision approaches
- Examining how early intelligence, coordinated data-sharing, and evidence generation can bridge the gap between scientific discovery and clinical impact
- Discussing how cross-sector collaboration between policy makers, regulators, and innovators can ensure Europe remains resilient against future infectious-disease and AMR challenges

Conference Day Two

Thursday, 26th March, 2026

12.00 Translating Phage Promise into Practice: Building the Evidence, Infrastructure & Oversight for Clinical Adoption

- Examining how phage therapy can be integrated into antimicrobial resistance strategies through real-world evidence generation and clinical trial design
- Discussing how coordinated reference networks, surveillance data, and stewardship systems can inform safe, scalable phage deployment across diverse healthcare settings
- Exploring what global infrastructure and cross-sector collaboration are needed to transition phage from exceptional use to a reliable therapeutic tool



Colin Brown

Head of Antimicrobial Resistance & Healthcare Associated Infections and Deputy Director: Epidemic & Emerging Infections

UKHSA

New Featured
Organisation



Mark Sutton

Professor for Antimicrobial Therapy & Scientific Leader - AMR and Healthcare Biotechnology

**King's College London &
UK Health Security Agency**

New Featured
Organisation



12.40 Lunch & Networking Break

From Bench to Bedside: Real-World Proof, Immunological Insight & Clinical Integration for Phage Therapy

1.40 Proving the Potential: What Happens When Phage Therapy Reaches the Bedside



Jean-Paul Pirnay

Head of the Laboratory for Molecular and Cellular Technology
Queen Astrid Military Hospital

- Sharing outcomes from Queen Astrid Military Hospital-based phage framework, which has delivered personalised treatments to more than 225 patients across 15 bacterial species
- Illustrating how direct clinical access to tailored phages is transforming outcomes for patients with otherwise untreatable infections
- Reflecting on lessons from expanding these efforts internationally, including collaborations in regions facing rising AMR, to show how pragmatic access models can drive real patient impact worldwide

2.10 Beyond Bacterial Lysis: Uncovering the Immunological Dimensions of Phage Therapy



Ryszard Międzybrodzki

Head of the Medical Center
**Ludwik Hirszfeld
Polish Academy of Sciences**

New Featured
Organisation

- Drawing on two decades of clinical experience and over 800 treated patients at Europe's first phage therapy centre, explore how therapeutic phages interact with the human immune system beyond their antibacterial activity
- Examining emerging data on the immunomodulatory and anti-inflammatory potential of phages, and how these mechanisms may open new therapeutic avenues for immune-mediated and chronic conditions
- Discussing how insights from patient treatment and immunological studies can inform regulatory dialogue, trial design and potency assessment, helping define safe and effective phage medicinal products for human use

2.40 Integrating Phage Therapy into Bone & Joint Infection Management: Clinical Insights from the UK Working Group



Antonia Scobie

Consultant & Research Lead - Bone Infection Unit
National Health Service (NHS)

New Featured
Organisation

- Exploring how the UK Clinical Working Group is shaping protocols for the safe and effective use of phage therapy in complex bone and joint infections
- Reviewing real-world experience from the Bone Infection Unit at the Royal National Orthopaedic Hospital, including patient selection, treatment pathways and clinical outcomes
- Discussing the practical, regulatory and microbiological considerations for combining phage therapy with conventional antimicrobial approaches in orthopaedic care



3.10 Afternoon Networking Break

Conference Day Two

Thursday, 26th March, 2026

Driving Precision Medicine in Phage Therapy to Deliver the Right Phage to the Right Patient at the Right Time



Catherine Rees
Professor of
Microbiology & Co-
Founder
**University of
Nottingham**

New Featured
Organisation

3.40 Leveraging Phage for Diagnostic Innovation: Lessons from Translating Lab Research into Commercial Reality

- Exploring how phage can be harnessed as powerful diagnostic tools to detect challenging pathogens such as mycobacteria in humans and animals
- Uncovering key learnings from taking phage-based diagnostics from academic research through validation, manufacturing and commercial development
- Identifying how advances in phage diagnostics can inform host-range testing, therapy selection and the broader clinical adoption of phage technologies



Stephanie Lesage
Chief Executive Officer
**Oxford Silk Phage
Technologies**

New Featured
Company

4.10 Reimagining Infection Prevention with Phage-Enhanced Medical Devices to Reduce Cardio Vascular-Associated Infections & Beyond

- Introducing bacteriophage-integrated biotextiles as a novel class of medical devices designed to prevent rather than treat infection
- Outlining pre-clinical validation progress and regulatory considerations for establishing phage-based infection prevention as a new medical-device standard
- Exploring future opportunities for precision prevention, tailoring phage-loaded devices to patients prone to recurrent infections



Amanda Burkardt
Chief Executive Officer
PhioGen

4.40 Rewriting Chronic Disease with Dual-Action Phage Therapeutics

- Rapid bacterial killing to shut down active disease
- Immune-driven prevention that blocks recurrence
- One platform addressing both infection and resistance

5.10 Chair's Closing Remarks

5.15 End of the 8th Bacteriophage Therapy Summit

“The Bacteriophage Therapy Summit brings together the science, the commercialisation strategy, and the shared purpose of building a real global field, not just isolated efforts. I’m looking forward to conversations that bridge lab and clinical results to community delivery. I’m eager to discuss how we actually get phage drugs to the people who need them.”

Chief Executive Officer & Co-Founder, **PhagePro - 2026 Speaker**

Lead the Charge at the 8th Bacteriophage Therapy Summit

8th Annual Bacteriophage Therapy Summit
24-26th March, 2026 | London, UK

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Your Unparalleled Opportunity to Connect with the Phage Industry's Leading Experts & Decision Makers

As the only, industry-dedicated conference bringing together C-Suite leaders from across the bacteriophage community, this summit provides an unparalleled opportunity for pioneers and decision makers to connect with solution providers who can overcome manufacturing bottlenecks, deliver bioinformatic insights that strengthen data interpretation, and enable the scalable, regulatory-compliant advancement of phage therapeutics from discovery to clinic.

Partnerships at this summit will allow you to:



Connect with Decision Makers

Build relationships with senior executives and scientific leaders shaping the global phage landscape, from biotech pioneers to agricultural leaders



Lead the Conversation

Position your expertise at the centre of discussions tackling the most pressing barriers in phage development, manufacturing, and commercialisation



Generate Commercial Opportunities

Showcase your solutions to a targeted audience actively seeking strategic collaborations and partnerships to accelerate phage therapies toward clinical and commercial success

As investment grows in this space, you need to **be the face the community remembers** to help them achieve their goals.

Seniority of Attendees




C-Level: 51%

Director: 12%

Head of, Manager, Lead, Other: 37%

Type of Companies Attending



Phage Developers

Service Providers

Academic Experts

Investors

*Statistics taken from the 7th Bacteriophage Therapy Summit

Get Involved



Adam Grosz
Senior Sponsorship Development Manager
Hanson Wade
Email: sponsor@hansonwade.com
Tel: +44 (0)20 3141 8700

Ready to Register?

3 Easy Ways to Book

 www.bacteriophage-summit.com

 Tel: +44 (0)20 3141 8700

 Email: info@hansonwade.com



DISCOVER how leading companies are harnessing advances in molecular engineering, formulation and delivery science to unleash the full therapeutic potential of next-generation phage-based treatments.



BUILD your understanding of the key challenges and strategies driving progress in phage discovery, characterization, manufacturing, and regulatory translation to clinical success.



ENGAGE with peers and pioneers from across the global phage community to forge meaningful collaborations, share practical solutions, and accelerate the delivery of safe, effective and scalable phage therapies to patients.

Phage Developers*	Register by Friday 12th December & Save Up to £1,000	On the Door Price
Conference + 2 Workshops	£2,197 (Save £1,000)	£3,197
Conference + 1 Workshop	£1,998 (Save £750)	£2,748
Conference Only	£1,799 (Save £500)	£2,299

Academic & Research Institutes**	Register by Friday 12th December & Save Up to £1,000	On the Door Price
Conference + 2 Workshops	£1,797 (Save £700)	£2,547
Conference + 1 Workshop	£1,598 (Save £625)	£2,223
Conference Only	£1,399 (Save £500)	£1,899

Solution & Service Providers	Register by Friday 12th December & Save Up to £1,000	On the Door Price
Conference + 2 Workshops	£2,997 (Save £1,000)	£3,997
Conference + 1 Workshop	£2,698 (Save £750)	£3,448
Conference Only	£2,399 (Save £500)	£2,899

*To qualify for the phage developer rate, your organisation must be actively developing bacteriophage products and have a publicly available development pipeline. Companies that provide fee-based services, solutions, technologies or consultancy to other organisations do not qualify. Please visit the website for full pricing options or email

**To qualify for the academic & research, you must be a full-time academic, employed by a research institute, or represent a non-profit organisation that does not sell services or solutions. Please visit the website for full pricing options or email info@hansonwade.com

VAT: If you are a UK or EU-based company, you may be subject to 20% VAT in addition to the price advertised. If you qualify for a reverse charge, you will have the option to provide your VAT number and the charge will be automatically deducted at checkout.

Team Discounts***

- 10% discount – 2 Attendees
- 15% discount – 3 Attendees
- 20% discount – 4+ Attendees

***Please note that discounts are only valid when two or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com



Venue

Novotel London West
1 Shortlands Hammersmith International Ctr
London W6 8DR
<https://www.novotellondonwest.co.uk/>

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Hanson Wade Ltd, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom



13

 +44 (0)20 3141 8700

 info@hansonwade.com

 www.bacteriophage-summit.com



WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE